Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Richard Law's Stock Ratings
Goldman Sachs Analyst
Richard Law is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/15/2025
Updated: Dec 15, 2025
Overall Average Return
25.6%
Smart Score
Overall Average Return Percentile
82nd
Number of Ratings
68
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/11/2025 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | 7.27% | $26 → $38 | Maintains | Buy | Get Alert | |
| 11/21/2025 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -26.61% | $18 → $26 | Maintains | Buy | Get Alert | |
| 09/09/2025 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | 40.6% | $32 → $52 | Maintains | Buy | Get Alert | |
| 08/07/2025 | VRDN | Buy Now | Viridian Therapeutics | $33.50 | -10.45% | $27 → $30 | Maintains | Buy | Get Alert | |
| 08/06/2025 | MLTX | Buy Now | MoonLake | $14.52 | 464.93% | $74 → $82 | Maintains | Buy | Get Alert | |
| 05/14/2025 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -49.19% | $20 → $18 | Maintains | Buy | Get Alert | |
| 05/09/2025 | RCKT | Buy Now | Rocket Pharmaceuticals | $3.48 | 274.1% | $15 → $13 | Maintains | Neutral | Get Alert | |
| 05/09/2025 | CLDX | Buy Now | Celldex Therapeutics | $27.31 | 13.51% | $36 → $31 | Maintains | Neutral | Get Alert | |
| 05/07/2025 | VRDN | Buy Now | Viridian Therapeutics | $33.50 | -19.4% | $31 → $27 | Maintains | Buy | Get Alert | |
| 03/03/2025 | RCKT | Buy Now | Rocket Pharmaceuticals | $3.48 | 331.65% | $29 → $15 | Maintains | Neutral | Get Alert | |
| 03/03/2025 | CLDX | Buy Now | Celldex Therapeutics | $27.31 | 31.82% | $42 → $36 | Maintains | Neutral | Get Alert | |
| 02/27/2025 | MLTX | Buy Now | MoonLake | $14.52 | 402.93% | $82 → $73 | Maintains | Buy | Get Alert | |
| 02/13/2025 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | -35.11% | $28 → $24 | Maintains | Buy | Get Alert | |
| 01/17/2025 | MLTX | Buy Now | MoonLake | $14.52 | 464.93% | $62 → $82 | Upgrade | Neutral → Buy | Get Alert | |
| 09/30/2024 | CLDX | Buy Now | Celldex Therapeutics | $27.31 | 64.77% | → $45 | Initiates | → Neutral | Get Alert | |
| 09/12/2024 | VRDN | Buy Now | Viridian Therapeutics | $33.50 | -7.46% | $25 → $31 | Maintains | Buy | Get Alert | |
| 06/06/2024 | VRDN | Buy Now | Viridian Therapeutics | $33.50 | -31.34% | → $23 | Initiates | → Buy | Get Alert | |
| 04/02/2024 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | -18.89% | → $30 | Initiates | → Buy | Get Alert | |
| 04/02/2024 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -32.25% | → $24 | Initiates | → Buy | Get Alert | |
| 04/02/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $3.48 | 1022.3% | → $39 | Initiates | → Neutral | Get Alert | |
| 04/02/2024 | MLTX | Buy Now | MoonLake | $14.52 | 327.14% | → $62 | Initiates | → Neutral | Get Alert | |
| 08/11/2023 | GLUE | Buy Now | Monte Rosa Therapeutics | $16.75 | -34.35% | → $11 | Reiterates | Neutral → Neutral | Get Alert | |
| 08/11/2023 | VERV | Buy Now | Verve Therapeutics | — | — | → $31 | Reiterates | Neutral → Neutral | Get Alert | |
| 08/09/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -49.19% | $16 → $18 | Maintains | Outperform | Get Alert | |
| 08/09/2023 | BEAM | Buy Now | Beam Therapeutics | $27.57 | 70.44% | $46 → $47 | Maintains | Neutral | Get Alert | |
| 08/08/2023 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | 0.04% | $38 → $37 | Maintains | Outperform | Get Alert | |
| 08/08/2023 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 9.43% | $62 → $63 | Maintains | Neutral | Get Alert | |
| 08/04/2023 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -56.96% | $36 → $37 | Maintains | Neutral | Get Alert | |
| 06/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 726.09% | → $76 | Reiterates | Outperform → Outperform | Get Alert | |
| 06/05/2023 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -58.12% | → $36 | Reiterates | Neutral → Neutral | Get Alert | |
| 05/16/2023 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | 2.74% | → $38 | Reiterates | Outperform → Outperform | Get Alert | |
| 05/12/2023 | FIXX | Buy Now | Homology Medicines | — | — | → $2 | Reiterates | Neutral → Neutral | Get Alert | |
| 05/12/2023 | GLUE | Buy Now | Monte Rosa Therapeutics | $16.75 | -34.35% | → $11 | Reiterates | Neutral → Neutral | Get Alert | |
| 05/09/2023 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 7.7% | $65 → $62 | Maintains | Neutral | Get Alert | |
| 05/08/2023 | EDIT | Buy Now | Editas Medicine | $2.54 | 451.16% | $15 → $14 | Maintains | Neutral | Get Alert | |
| 05/08/2023 | ARVN | Buy Now | Arvinas | $12.62 | 383.36% | → $61 | Reiterates | → Outperform | Get Alert | |
| 05/05/2023 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -58.12% | $39 → $36 | Maintains | Neutral | Get Alert | |
| 03/17/2023 | GLUE | Buy Now | Monte Rosa Therapeutics | $16.75 | -34.35% | $12 → $11 | Maintains | Neutral | Get Alert | |
| 03/16/2023 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | 2.74% | $40 → $38 | Maintains | Outperform | Get Alert | |
| 03/10/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -68.95% | $12 → $11 | Maintains | Outperform | Get Alert | |
| 03/07/2023 | MLYS | Buy Now | Mineralys Therapeutics | $36.98 | 8.15% | → $40 | Initiates | → Outperform | Get Alert | |
| 02/24/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 726.09% | $88 → $76 | Maintains | Outperform | Get Alert | |
| 02/24/2023 | ARVN | Buy Now | Arvinas | $12.62 | 383.36% | $81 → $61 | Maintains | Outperform | Get Alert | |
| 02/24/2023 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -54.63% | $32 → $39 | Maintains | Neutral | Get Alert | |
| 02/23/2023 | EDIT | Buy Now | Editas Medicine | $2.54 | 490.53% | $13 → $15 | Maintains | Neutral | Get Alert | |
| 02/22/2023 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 12.91% | $78 → $65 | Maintains | Neutral | Get Alert | |
| 02/22/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $35.42 | -66.13% | → $12 | Initiates | → Outperform | Get Alert | |
| 12/06/2022 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 856.52% | $109 → $88 | Maintains | Outperform | Get Alert | |
| 12/06/2022 | EDIT | Buy Now | Editas Medicine | $2.54 | 411.79% | → $13 | Assumes | → Neutral | Get Alert | |
| 12/06/2022 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -62.77% | $47 → $32 | Downgrade | Outperform → Neutral | Get Alert | |
| 11/08/2022 | BEAM | Buy Now | Beam Therapeutics | $27.57 | 92.2% | $65 → $53 | Maintains | Neutral | Get Alert | |
| 11/04/2022 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -45.32% | $61 → $47 | Maintains | Outperform | Get Alert | |
| 11/04/2022 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 1084.78% | $101 → $109 | Maintains | Outperform | Get Alert | |
| 11/02/2022 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 35.49% | $90 → $78 | Maintains | Neutral | Get Alert | |
| 10/06/2022 | VERV | Buy Now | Verve Therapeutics | — | — | → $48 | Initiates | → Neutral | Get Alert | |
| 08/16/2022 | FIXX | Buy Now | Homology Medicines | — | — | $3.1 → $3.21 | Maintains | Neutral | Get Alert | |
| 08/10/2022 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -29.04% | $60 → $61 | Maintains | Outperform | Get Alert | |
| 08/09/2022 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 56.33% | $74 → $90 | Maintains | Neutral | Get Alert | |
| 08/05/2022 | ARVN | Buy Now | Arvinas | $12.62 | 518.07% | $98 → $78 | Maintains | Outperform | Get Alert | |
| 05/17/2022 | FIXX | Buy Now | Homology Medicines | — | — | $2.7 → $2.1 | Maintains | Neutral | Get Alert | |
| 05/06/2022 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 965.22% | $100 → $98 | Maintains | Outperform | Get Alert | |
| 04/28/2022 | CRSP | Buy Now | CRISPR Therapeutics | $57.57 | 35.49% | → $78 | Initiates | → Neutral | Get Alert | |
| 04/28/2022 | ARVN | Buy Now | Arvinas | $12.62 | 724.09% | → $104 | Initiates | → Outperform | Get Alert | |
| 04/28/2022 | BEAM | Buy Now | Beam Therapeutics | $27.57 | 124.84% | → $62 | Initiates | → Neutral | Get Alert | |
| 04/28/2022 | GLUE | Buy Now | Monte Rosa Therapeutics | $16.75 | 13.4% | → $19 | Initiates | → Neutral | Get Alert | |
| 04/28/2022 | KYMR | Buy Now | Kymera Therapeutics | $85.96 | -26.71% | → $63 | Initiates | → Outperform | Get Alert | |
| 04/28/2022 | FIXX | Buy Now | Homology Medicines | — | — | → $2.7 | Initiates | → Neutral | Get Alert | |
| 04/28/2022 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 986.96% | → $100 | Initiates | → Outperform | Get Alert |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved